Please login to the form below
mongersen
This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.
Latest news
-
Celgene pays $300m upfront for immunology start-up Delinia
other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Senior Account Manager
-
Competitive Salary Offered
-
Medical Writer
-
Salary TBC
-
Associate Director
-
£75, 000-90, 000
-
Account Director
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Global Business Development Director – Health Education
-
excellent commission
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Account Director, Medical Education
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
Subscribe to our email news alerts
- Pfizer takeover rumour ignites Amarin shares
- Welcome to the Communique Awards - Communiqué Awards 2018
- NICE rejects Novartis migraine treatment Aimovig
- AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief
- GSK upbeat on its return to oncology market
- BMS and Celgene deal sparks debate on pharma profit motive, more M&A
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- The UK’s new five-year pricing agreement
- Lucid kick-starts 2019 with spellbinding new additions to its writing and account teams
- New hires at Nanoform, Leo Pharma and Calliditas
- Page & Page welcomes Clare Bates to the team
- Lucid Group prepare for a transformative year with the appointment of a new Director of Corporate Development
PMHub
Star
We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...
Latest intelligence
- The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
- ...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again – in exchange for uptake promises...
- Digital applications are transforming the market access landscape
- Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Quick links
Infographics
